NeuBase Therapeutics, Inc.
Verified IntelNeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase’s pipeline includes therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington's disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.”
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase’s pipeline includes therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington's disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.”
Corporate Firmographics
Entity classification and operating profile
- Industry
- Pharmaceuticals
- Company Type
- Public Company
- Founded
- 2018
- Employee Bracket
- 11-50
- Estimated Revenue Range
- Undisclosed
Geographic Coordinates
Headquarters address and regional territory
- Street Address
- 350 Technology Drive Pennsylvania Pittsburgh
- City
- Pittsburgh
- Region / State
- Pennsylvania
- Postal Code
- 15219
- Country
- United States
Digital Presence & Footprint
Verified domains, socials, and directory profiles
Frequently Asked Questions
Verified business inquiries and firmographic telemetry for NeuBase Therapeutics, Inc..